drugset

drugset / Trial / NCT00108095

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

NCT00108095 ↗

Phase 2 Completed 701 enrolled GlaxoSmithKline

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV

Timeline

Start: 2004-10
Primary completion: 2005-08
Completion: 2005-08

Publications

Background Singla NK, Singla SK, Chung F, Kutsogiannis DJ, Blackburn L, Lane SR, Levin J, Johnson B, Pergolizzi JV Jr. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010 Jul;113(1):74-82. doi: 10.1097/ALN.0b013e3181d7b13a.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Ondansetron	Other / unclassified	—	Intravenous

Indications

No indication recorded.